

DIGESTIVE DISEASE AND NUTRITION CENTER OF WESTCHESTER, LLP.

JACK ROSEMARIN, M.D., F.A.C.G.
ALFRED D. ROSTON, M.D., F.A.C.G.
CHARLES M. NOYER, M.D., F.A.C.P.
DEBORAH HILLMAN, M.D.
GERALYN PLOMITALLO, R.D., C.D.E.



TWO GANNETT DRIVE
WHITE PLAINS, NEW YORK 10604
TELEPHONE: (914) 683-1555
FAX: (914) 683-1026
WWW.STOMACHMDS.COM

April 2, 2007

Dear Patients,

Last week Novartis, the manufacture of Zelnorm announced that it is complying with an FDA request to suspend marketing of Zelnorm.

A recent analysis of clinical trial data identified a small imbalance that was statistically significant in the number of cardiovascular ischemic events in patients taking Zelnorm. These events included heart attack, stroke and unstable angina. They occurred primarily in patients who had pre-existing cardiovascular disease and/or cardiovascular risk factors. There is no demonstrated causal relationship between Zelnorm and these events, so you should not be worried about a cardiovascular event.

Patients who are taking Zelnorm should call our office to discuss appropriate treatment options. Patients can return any unused and unexpired Zelnorm tablets to Novartis for reimbursement of out-of-pocket costs. More information can be obtained by calling the Novartis Customer Interaction Center at 888-NOW-NOVA (888-669-6682).

Patients who are using Zelnorm in conjunction with a preparation for a colonoscopy or other procedure should follow the preparation given by their physician without using Zelnorm.

If you have any questions, please feel free to contact your physician at (914) 683-1555.

Sincerely,

Jack Rosemarin, M.D., F.A.C.G.

Alfred Roston, M.D., F.A.C.G.

Charles Noyer, M.D., F.A.C.P.

Deborah Hillman, M.D.